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Abstract 
Background: There is little evidence regarding the optimal duration of antibiotic therapy for diabetic foot osteomyelitis (DFO). So, the 
optimal duration of antibiotic treatment of osteomyelitis complicating foot wounds in non–surgically treated diabetic patients is currently 
unknown and needs more studies in the future. This study aimed to compare six-week versus twelve-week antibiotic therapy for the 
treatment of nonsurgical DFO. 
Methods: This was an interventional study that was performed on 30 patients with DFO without surgical indications who were randomly 
divided into two groups (six-week versus twelve-week antibiotic therapy). Changes of parameters such as C-reactive protein (CRP), 
albumin, erythrocyte sedimentation rate (ESR), HbA1c, creatinine, fasting blood sugar (FBS) at baseline, FBS after two hours, white 
blood cell (WBC), absolute count of neutrophil and clinical outcomes (percentage of complete healing and non-healing, the time of 
complete healing, radiological abnormality and recurrence of the disease after treatment) were measured in the two groups and then 
analyzed by statistical methods in SPSS version 21.  
Results: During the study period, values of CRP (p=0.03), ESR (p=0.03), two-hour glucose (p=0.02), WBC (p=0.04) and absolute 
neutrophil count (p=0.04) in the six-week treatment group and the values of CRP (p=0.02), ESR (p=0.02), HbA1c (p=0.04), FBS at 
baseline (p=0.04), FBS after two-hour (p=0.01), WBC (p=0.02) and absolute neutrophil count (p=0.04) in the twelve-week treatment 
group changed significantly. There was no significant difference concerning the clinical outcomes between the two groups. 
Conclusions: The results showed that six and twelve-week antibiotic therapy had the same efficacy in the treatment of non-surgically 
DFO. Therefore, six-week antibiotic therapy of DFO could be sufficient in these patients. 
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Introduction 
Patients with diabetes mellitus are at risk of severe infections due to neuropathy, vascular dysfunction and decreased neutrophil function, 
that of them, neuropathy is very important [1,2]. Today, the incidence of foot ulcer in diabetic patients ranges from 4% to 10% which is 
reported to be 1.5% to 3.5% in young people, 5% to 10% in the elderly and of them less than 3.6% belong to patients with type I and II 
diabetes yearly [1]. Food infection has different clinical manifestations, especially osteomyelitis in diabetic patients can ultimately lead to 
lower limb amputation. The successful treatment of diabetic foot osteomyelitis (DFO) depends on the proper administration of antibiotics, 
debridement of the wound and control of blood glucose levels [1,3]. 
More recent clinical studies have shown that DFO can be prevented in more patients by using antibiotic therapy without bone amputation. 
So, the optimal duration of antibiotic treatment of osteomyelitis complicating foot wounds in non-surgically treated diabetic patients is 
currently unknown and needs more studies in the future [4,5]. 
By considering the various complications of antibiotics, determining the optimal time to antibiotics prescription, its type and amount, 
method and duration of administration are important. Treatment is usually started empirically and treatment protocols should be selected 
according to the severity of the infection, previous treatment, previous culture responses, presence and absence of drug sensitivity and 
liver and kidney function status. Depending on the severity of the infection and response to treatment with the use of various antibiotics 
as injectable and then orally, treatment may require to be continued for up to twelve weeks [6-10]. However, the optimal duration of 
antibiotic treatment of osteomyelitis complicating foot wounds in non-surgically treated diabetic patients is currently unknown and needs 
more studies [11]. Based on recent studies, the six-week antibiotic therapy in patients with non-surgical DFO could be sufficient [12]. 
Based on available studies, antibiotic therapy has been associated with significant improvement by using compounds such as rifampin 
and fluoroquinolones on average after 12 months of continuous follow-up. So, in patients with DFO, reducing the duration of treatment 
may help reduce medical interventions and their consequences [11]. The aim of this study was to compare six-week versus twelve-week 
antibiotics therapy for the treatment of non-surgically DFO. 
 
Methods 
Study design and sample size 
This prospective interventional study was conducted on 30 hospitalized patients with DFO without surgical indications or amputation who 
referred to the diabetes clinic of Ardabil City Hospital. The sample size was calculated based on 80% power analysis, 95% confidence 
interval by estimated necessary parameters from similar studies and used the necessary formula for sample size in a randomized clinical 
trial.  
 
Patient’s selection criteria 
Patients with a diagnosis of DFO without surgical indications were selected based on clinical examination such as bone probe test, 
radiography, laboratory diagnosis (including leukocytosis, ESR) and divided randomly by random table data generation into two groups 
of clindamycin and ciprofloxacin which received antibiotic for six and twelve-week, respectively. Two groups were compared in terms of 
wound healing and response to treatment at the end of the study. 
 
Inclusion and exclusion criteria 
DFO patients with no surgical osteomyelitis, no chronic liver, kidney and coronary artery disease, anemia, rheumatism, lack of drug  
resistance to ciprofloxacin and clindamycin, without history of ciprofloxacin use in recent year and severe obesity (BMI above 30) were  
included in the study and patients who need for surgical intervention in any time, presence any causes of the disorder during follow-up 
time and treating patients, presence of the etiologic factors against the used antibiotics, none of anterior and posterior foot pulses (using  
arterial  Doppler test), history of gastrointestinal complications, history of drug side effects such as gastrointestinal side effects of 
ciprofloxacin and clindamycin during the study, drug resistance to ciprofloxacin and clindamycin and also pregnant women were excluded 
from the study. 
 
Treatment and criteria for response to treatment 
All patients in both groups, in addition to antibiotics, received a similar dose of aspirin, losartan, atorvastatin and insulin. One group 
received clindamycin for six weeks and another group received ciprofloxacin for twelve weeks by oral administration for the entire duration 
of treatment. The two groups were followed about three months for relapse based on clinical and laboratory findings. The response criteria 
to the treatment include absence of scarring, absence of bad scent, decreasing trend of ESR, improvement of systemic symptoms and 
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fever with osteomyelitis origin and improvements in radiographic criteria. The criteria for recurrence of osteomyelitis include wound 
secretion, scarlet smell, high ESR and fever with osteomyelitis origin. 
 
Ethical considerations 
This research was registered at the Ethics Committee of the Ardabil University of Medical Sciences by code IRI-ARUMS-REC-1395-54 
and at the Iranian Clinical Trials System (IRCT) by code IRCT 2016110830793N1. This study was conducted in accordance with the 
declaration of Helsinki and informed consent was obtained from all participants. 
 
Statistical analysis 
Collected data were analyzed by using the ANOVA test to compare the continuous variables between more groups and χ2 test for 
comparing the difference between the frequency of recovery or failure rates between two groups in SPSS version 23. The p<0.05 was 
considered as significant.  
 
Results 
The two groups were the same in terms of age, gender, height, weight, BMI, depth of wound and location of wound (Table 1). 
 
Table 1. Demographic characteristics of studied patients 
Variables  6 weeks 12 weeks All patients p 
Gender (f/m) 4/11 4/11 8/22 1 
Age, years, mean±SD  52.8 ± 6.5 5.8 ± 53.3 6.1 ± 53.2 0.77 
Height (cm) 10 ± 173 175 ± 11 9 ± 174 0.61 
Weight (kg) 82.1 ± 9.5 6.3 ± 83 7.4 ± 84 0.8 
BMI (kg/m2) 27.4 ± 1.5 2.7 ± 27.1 2.1 ± 27.7 0.83 
Radiographic criteria need to elaborate 11 (73.3%) 13 (86.6%) 24 (80%) 0.42 
Size of ulcer (mm2) 11.2 ± 3.5 9.1 ± 2.7 10.1 ± 3.1 0.21 
Depth of ulcer (mm) 1.24 ± 6.4 1.34 ± 6.6 6.5 ± 1.74 0.71 
Positive probe-to-bone test  )100%( 15 )100%( 15 30 (100%) 1 
Location of ulcer  Metatarsal head of the 
first ray 
)33.3%( 5 )40%( 6 )36.6%( 11 0.87 
Metatarsal head of the 
fifth ray 
)26.6%( 4 )26.6%( 4 )26.6%( 8 1 
Other metatarsal 
locations 
)26.6%( 4 )13.3%( 2 )20%( 6 0.49 
Hallux  )20%( 3 )13.3%( 2 )16.6%( 5 0.53 
Surface of wound, mm2, mean±SD 9.1 ± 2.7 10.1 ± 3.1 11.2 ± 3.5 0.2 
Depth of wound, mm2, mean±SD 6.6 ± 1.34 6.5 ± 1.74 6.4 ± 1.24 0.7 
 
There were no significant differences between the two groups regarding the administration duration of antibiotics based on laboratory 
findings (Table 2). 
There was no significant difference in the incidence of adverse effects between the two drug groups (Table 3). 
After the intervention, the values of CRP (p=0.03), ESR (p=0.03), two-hour glucose (p=0.02), total white blood cell (p=0.04) and absolute 
neutrophil (p=0.04) had a significant difference between the two groups (Table 4). 
There was no significant difference between the two groups in the complete recovery rate and the recovery rate was slightly higher in the 
twelve-week treatment group than the six-week treatment group and the minimum recovery time was obtained from the fourth week after 
the start of treatment (Table 5). 
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Table 2. Biochemical and blood parameters of the patients at baseline  
Variables  6 weeks 12 weeks All patients p 
CRP (mg/L) 4.5 ± 17.1 3.5 ± 918. 14. ± 2.17 52.0 
Albumin (g/dL) 0.7 ± 3.6  3.5 ± 0.9 40. ± 53. 330. 
ESR (mm/hour) 62.3 ± 20.3 3.24 ± 267. 22.4 ± 2.64 41.0 
HBA1c (%) 8.9 ± 0.6 .70 ± .39 11. ± 21.9 22.0 
Creatinine (mg/dL) 1.11 ± 0.3 .40 ± 361. 41.0 ± 21.1 82.0 
FBS (mg/dL) .217 ± 154.4 1.13 ± 1.163 .214 ± 7.158 45.0 
Glucose (two-hour late) 11.4 ± .5286 .119 ± 1.280 24.9 ± 7281. 42.0 
WBC .31 ± .410 .11 ± 61.10 41. ± 5.10 78.0 
Neutrophils  116 ± 8424 118 ± 8798 235 ± 8610 340. 
RBC .60 ± 5.7 5.6 ± 0.8 7.0 ± 6.5 700. 
Hb (g/dL) .31 ± 14.4 1.2 ± 614. 42. ± 514. 430. 
HCT (%) 4 ± 43.4 .34 ± 2.45 4.4 ± .345 33.0 
MCV 2.6 ± 484. .17 ± 390. 4.5 ± 3.88 37.0 
MCH (pg) 2.4 ± 4.32 .25 ± 2.33 2.3 ± 1.32 47.0 
MCHC (%) 1.1 ± 1.33 .21 ± 4.33 41. ± 2.33 78.0 
Platelet (l/105) .245 ± 5.292 .154 ± 1.279 .944 ± 7.286 37.0 
 
Table 3. Outcomes after the intervention  
Outcomes 6-week treatment group 
N (%) 
12-week treatment group 
N (%) 
p 
Nausea )66.( 1 )20( 3 120. 
Vomiting ).66( 1 )13.3( 2 41.0 
Diarrhea )6.6( 1 ).313( 2 410. 
 
Table 4. Blood and biochemical markers of patients after the intervention (6-month antibiotic therapy)  
Biochemical and 
blood markers  
Status   0 2 4 6 p 
CRP (mg/L) 
 
Improved 63. ± 0217. 7.7 ± 14.2 1.4 ± 32.9 2.1 ± 4.32 0.03 
Non-Improved 44. ± 1117. 31.5 ± 16.55 .433 ± 15.2 4.47 ± .7317 0.43 
Albumin (g/dL) 
 
Improved 4.0 ± .63 40. ± 3.5 .60 ± 3.4 3.0 ± 3.5 0.67 
Non-Improved 8.0 ± .63 0.2 ± .53 0.5 ± 3.3 90. ± 3.3 0.39 
ESR (mm/hour) Improved 418.	± 264. 54.3 ± 17.4 47.3 ± 11.6 37.3 ± 12.4 0.03 
Non-Improved 21.4 ± 266. 61.3 ± 17.5 57.3 ± 23.4 54.3 ± 17.6 0.4 
HBA1c (%) Improved 8.67 ± 0.6 8.54 ± 0.7 8.57 ± 0.6 8.62 ± 0.8 0.51 
Non-Improved 8.91 ± 0.5 8.78 ± 0.8 8.72 ± 0.8 8.67 ± 0.5 0.53 
Creatinine (mg/dL) Improved 1.11 ± 0.3 1.23 ± 0.5 1.21 ± 0.4 1.18 ± 0.4 0.66 
Non-Improved 1.16 ± 0.7 1.21 ± 0.3 1.19 ± 0.6 1.2 ± 0.2 0.71 
FBS (mg/dL) Improved .210 ± 154.4 .316 ± 149.1 .315 ± .1148 16.2 ± 147.1 0.26 
Non-Improved 17.3 ± 156.4 .613 ± 150.4 .414 ± 153.2 .311 ± 153.1 0.73 
Glucose (two-hour late) Improved 24.5 ± 282.5 250.5 ± 11.5 13.2 ± 235.5 .120 ± 201.5 0.02 
Non-Improved 4.26 ± 289.5 17.7 ± 265.5 .510 ± 274.5 17.4 ± 276.5 0.77 
WBC Improved .71 ± 10.6 .62 ± 8.7 .32 ± 8.4 .91 ± 7.4 0.04 
Non-Improved .11 ± .310 2.3 ± 9.4 .22 ±	8.7 .82 ± 8.7 0.52 
Neutrophils Improved 223 ± 8624 954 ± 7528 435 ± 7132 601 ± 7096 0.04 
Non-Improved 221 ± 8342 789 ± 7731 763 ± 7535 980 ± 7712 0.56 
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Table 5. Clinical results of the treatment at the end of study (6 and 12 weeks after the intervention)  
Results   6-week treatment group  
N (%) 
12-week treatment group 
N (%) 
p 
Complete improvement  11 (78.6) 11 (84.6) 0.74 
Non-improvement  3 (21.4) 2 (15.4) 0.61 
Time of complete improvement 11.6 ± 14.8 .115 ± .217 0.23 
Severity of radiologic symptoms 2 (14.3) 1 (7.7) 0.34 
Relapse after stopping treatment  1 (7.1) 1 (7.7) 0.92 
 
Discussion 
The results indicated that six-week treatment of DFO patients without surgical indications had similar results to the twelve-week treatment 
group. In patients with the diabetic foot without bone infections, the duration of antibiotic treatment was typically twelve-week [12]. So, 
there was no evidence about the effect of antibiotic therapy for more than six weeks on the rate of disease recovery. According to the 
American Infectious Disease Association, antibiotic therapy should continue for six to twelve weeks in the course of persistent bone and 
soft tissue infection. Also, antibiotics should be given for twelve-week or more in patients who have not been treated for necrosis and 
infection of the bone for any reasons. The results of this study confirmed the possibility of treatment of DFO without surgical indication 
with six-week antibiotic administration. According to available reports, antibiotic therapy and surgical treatment of patients with neuropathic 
ulcers with non-ischemic osteomyelitis or soft tissue necrosis had similar results [12-15]. DFO therapy due to side effects of antibiotics, 
particularly bacterial and diarrheal (caused by Clostridium Difficile), as well as its cost-effectiveness is often considered as a side 
therapeutic approach. In this study, gastrointestinal complications were observed in both groups, but the proportion of these complications 
was higher in the twelve-week treatment group than the six-week treatment group. Reducing the duration of antibiotic therapy deals to 
reduce the undesirable and negative effects of drugs on the bacterial intestinal flora and so, the observation of the low ratio of 
gastrointestinal disorders in the six-week treatment group also confirms this. Tone et al, in their study, showed that rifampin and 
ciprofloxacin had same effects on DFO which in line with our study results and in 10% of patients in twelve-week treatment group, they 
observed gastrointestinal complications [12,14-17]. In this study, in both groups, CRP values showed a significant decreasing trend in 
patients during the treatment period. Regarding that CRP is one of the positive acute-phase proteins, reducing its levels in infectious and 
inflammatory conditions such as DFO indicates improvement in the condition of the disease and the response to the treatment as well as 
the reduction of the processes involved in the occurrence of inflammation. This protein increases faster than other acute-phase proteins 
and returns to the normal level sooner than other markers [16-19]. The findings of this study were in line with other reports about changes 
in this protein level during study and results of DFO treatment [11,16,18]. Plasma albumin, unlike CRP, did not show a significant change 
in this study in the two groups. This protein is a negative acute-phase protein which is changed based on infectious and inflammatory 
processes in the direction of the decreasing trend [3,12]. Considering that this protein has slightly changed over time in both groups, this 
could be a sign to the positive response to treatment in this study. The ESR like CRP showed a significant decrease in both groups. ESR 
can be used for follow-up trend of response to treatment of patients with osteomyelitis and its changes in comparison to other proteins 
had a slower trend [17,19]. ESR has been multiplied in osteomyelitis cases, so, its significant decrease in patients in both studied groups 
compared to untreated patients could be a reason for the positive response to treatment and recovery in this study. According to the Barati 
et al study, ESR levels in diabetic patients without bone involvement were significantly lower than patients with DFO (p=0.001) [18]. In a 
study performed in Boston, ESR and CRP levels in penetrating skin ulcers were higher in diabetic patients than non-diabetic and non-
ulcerated diabetic patients [18]. Other studies in this area also suggest an increase in ESR in cases of bone involvement that was in line 
with the findings of this study. In the present study, the HbA1c levels only showed a significant decreasing trend in patients with the twelve-
week treatment group. Given the fact that this scale shows blood glucose changes in the past three months, so observing this change in 
this group is obvious. If changes in glucose and fasting glucose levels are considered both measurements in both groups have significantly 
decreased in the patients and this itself indicates the control of blood glucose in these patients. Asten et al and Tone et al have shown 
similar changes in HbA1c levels and their results were consistent with the results of this study [12,17]. 
In this study, the total number of WBC, as well as the absolute number of neutrophils, had significant changes and their values decreased 
in both groups in improved patients. Given that one of the reasons for them is inflammatory and infectious diseases, so, a significant 
decrease of them showed the positive trend of improvement and repair of DFO in patients in the two groups. The results of this study 
were in line with other reports on the decreasing trend of the above values in the treatment of DFO [9,17-18]. 
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Conclusion 
The results of this study suggest that six-week duration of antibiotic therapy for DFO treated no surgically is associated with a similar 
outcome to that of twelve-week duration and also the gastrointestinal complications in the six-week treatment group were lower than the 
other group. Additionally, given the fact that MRI is the golden standard method for the diagnosis of osteomyelitis, it is recommended to 
be used in the future for all non-surgically DFO patients. 
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